Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on December 13, 2021. The filing reports a material change in corporate leadership regarding the departure of a senior officer and the appointment of a successor.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Departure: Masaru Matsuda will step down as Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary, effective December 31, 2021.
- Succession: Mark Snyder will be appointed to the same roles (Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary), effective January 3, 2022.
- Background: Mr. Snyder previously served as Senior Vice President and Deputy General Counsel, Litigation at Qualcomm Incorporated.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or specific risk factors. Regarding the departure, the Company intends to enter into a separation agreement with Mr. Matsuda providing benefits consistent with those disclosed in a prior Form 8-K filed on December 13, 2018. No unusual items or contingencies were reported in this document.
Key Facts for Investor Verification
- Verify the specific terms of the separation agreement with Masaru Matsuda by reviewing the Company's Form 8-K filed on December 13, 2018.
- Confirm the effective date of Mark Snyder's appointment (January 3, 2022) and his transition into the General Counsel role.
- Note that this filing does not impact the Company's financial reporting status or emerging growth company designation.